These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

430 related items for PubMed ID: 30062376

  • 1. Herpes zoster vaccine: a protection for the elderly.
    Di Pietro A, Facciolà A, Visalli G.
    Ann Ig; 2018; 30(4 Supple 1):23-27. PubMed ID: 30062376
    [Abstract] [Full Text] [Related]

  • 2. [Herpes Zoster and its prevention in Italy. Scientific consensus statement].
    Franco E, Gabutti G, Bonanni P, Conversano M, Stefano Valente ME, Ferro A, Icardi G, Antonio Volpi ML, Maggi S, Rossi A, Scotti S, Vitale F, Greco D, Italian Universities and Epidemiology.
    Ig Sanita Pubbl; 2014; 70(1):111-27. PubMed ID: 24770367
    [Abstract] [Full Text] [Related]

  • 3. [Pain in herpes zoster: Prevention and treatment].
    Calvo-Mosquera G, González-Cal A, Calvo-Rodríguez D, Primucci CY, Plamenov-Dipchikov P.
    Semergen; 2017; 43(4):318-327. PubMed ID: 27053513
    [Abstract] [Full Text] [Related]

  • 4. Vaccination: a new option to reduce the burden of herpes zoster.
    Mick G.
    Expert Rev Vaccines; 2010 Mar; 9(3 Suppl):31-5. PubMed ID: 20192716
    [Abstract] [Full Text] [Related]

  • 5. Herpes Zoster and Postherpetic Neuralgia: a review of the effects of vaccination.
    Johnson RW.
    Aging Clin Exp Res; 2009 Jun; 21(3):236-43. PubMed ID: 19571648
    [Abstract] [Full Text] [Related]

  • 6. [Herpes zoster in old adults].
    Lang PO, Belmin J, Michel JP.
    Presse Med; 2009 Apr; 38(4):571-83. PubMed ID: 19028069
    [Abstract] [Full Text] [Related]

  • 7. Zoster vaccine (Zostavax): a review of its use in preventing herpes zoster and postherpetic neuralgia in older adults.
    Sanford M, Keating GM.
    Drugs Aging; 2010 Feb 01; 27(2):159-76. PubMed ID: 20104941
    [Abstract] [Full Text] [Related]

  • 8. Public Health Impact and Cost-Effectiveness of Non-live Adjuvanted Recombinant Zoster Vaccine in Canadian Adults.
    McGirr A, Van Oorschot D, Widenmaier R, Stokes M, Ganz ML, Jung H, Varghese L, Curran D.
    Appl Health Econ Health Policy; 2019 Oct 01; 17(5):723-732. PubMed ID: 31250218
    [Abstract] [Full Text] [Related]

  • 9. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.
    Hornberger J, Robertus K.
    Ann Intern Med; 2006 Sep 05; 145(5):317-25. PubMed ID: 16954357
    [Abstract] [Full Text] [Related]

  • 10. Herpes zoster in Belgium: a new solution to an old problem.
    Nikkels AF, Schoevaerdts D, Kauffmann F, Strubbe F, Bensemmane S.
    Acta Clin Belg; 2024 Jun 05; 79(3):205-216. PubMed ID: 38781037
    [Abstract] [Full Text] [Related]

  • 11. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.
    Pellissier JM, Brisson M, Levin MJ.
    Vaccine; 2007 Nov 28; 25(49):8326-37. PubMed ID: 17980938
    [Abstract] [Full Text] [Related]

  • 12. Development of adjuvanted recombinant zoster vaccine and its implications for shingles prevention.
    Lecrenier N, Beukelaers P, Colindres R, Curran D, De Kesel C, De Saegher JP, Didierlaurent AM, Ledent EY, Mols JF, Mrkvan T, Normand-Bayle M, Oostvogels L, Da Silva FT, Vassilev V, Vinals C, Brecx A.
    Expert Rev Vaccines; 2018 Jul 28; 17(7):619-634. PubMed ID: 30028651
    [Abstract] [Full Text] [Related]

  • 13. [Active immunoprophylaxis to reduce clinical impact of Herpes Zoster and its complications].
    Marino MG, Bagnato B, Torella I, Franco E.
    Ig Sanita Pubbl; 2009 Jul 28; 65(3):299-311. PubMed ID: 19629155
    [Abstract] [Full Text] [Related]

  • 14. Herpes zoster vaccine effectiveness and manifestations of herpes zoster and associated pain by vaccination status.
    Marin M, Yawn BP, Hales CM, Wollan PC, Bialek SR, Zhang J, Kurland MJ, Harpaz R.
    Hum Vaccin Immunother; 2015 Jul 28; 11(5):1157-64. PubMed ID: 25806911
    [Abstract] [Full Text] [Related]

  • 15. Herpes zoster vaccine: A health economic evaluation for Switzerland.
    Blank PR, Ademi Z, Lu X, Szucs TD, Schwenkglenks M.
    Hum Vaccin Immunother; 2017 Jul 03; 13(7):1495-1504. PubMed ID: 28481678
    [Abstract] [Full Text] [Related]

  • 16. Vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia.
    Betts RF.
    J Am Acad Dermatol; 2007 Dec 03; 57(6 Suppl):S143-7. PubMed ID: 18021866
    [Abstract] [Full Text] [Related]

  • 17. [Prevention of herpes zoster by vaccination].
    Kofoed K, Rønholt F, Gerstoft J, Sand C.
    Ugeskr Laeger; 2011 Jan 10; 173(2):110-4. PubMed ID: 21219841
    [Abstract] [Full Text] [Related]

  • 18. A novel vaccine (Zostavax) to prevent herpes zoster and postherpetic neuralgia.
    Holcomb K, Weinberg JM.
    J Drugs Dermatol; 2006 Oct 10; 5(9):863-6. PubMed ID: 17039651
    [Abstract] [Full Text] [Related]

  • 19. A systematic review of the cost effectiveness of herpes zoster vaccination.
    Szucs TD, Pfeil AM.
    Pharmacoeconomics; 2013 Feb 10; 31(2):125-36. PubMed ID: 23335045
    [Abstract] [Full Text] [Related]

  • 20. A retrospective cohort study evaluating the incidence of herpes zoster and postherpetic neuralgia after a live attenuated Oka-strain herpes zoster vaccine in a real-world setting in Japan.
    Yaegashi M, Matsui H, Yoshida A, Ban H, Miyazaki R, Oda N, Hattori K, Motomura Y, Usami H, Matsushita H.
    Vaccine; 2024 Jan 25; 42(3):464-470. PubMed ID: 38172019
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.